Verve Therapeutics Jobs and Company Culture | Powderkeg
2022 Top Rated Biotech
Verve Therapeutics logo

Verve Therapeutics

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

BioTech
Cambridge, MA
$25M-100M

Funding

51-100

Employees

Is Verve Therapeutics the next step in your tech career? Find out now.

Company Mission

Protecting the world from heart disease
Looking for a better job?

Discover the best career opportunities with the best company cultures for you.

Do you work at this company?

Connect your business to thousands of engaged professionals in your city and beyond.